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Abstract
Recent findings have highlighted roles played by innate cellular factors in restricting intracellular
viral replication. In this review, we discuss in brief the activities of apolipoprotein B mRNA-editing
enzyme 3G (APOBEC3G), bone marrow stromal cell antigen 2 (BST-2), cyclophilin A, tripartite
motif protein 5 alpha (Trim5α), and cellular microRNAs as examples of host restriction factors that
target HIV-1. We point to countermeasures encoded by HIV-1 for moderating the potency of
these cellular restriction functions.
A brief overview of HIV-1/acquired immune 
deficiency syndrome (AIDS)
AIDS was first recognized nearly 30 years ago. The initial
description was followed shortly by the discovery and
characterization of its causative agent, the human immu-
nodeficiency virus, HIV-1. Today, approximately 33 mil-
lion people worldwide are infected with HIV. Each year,
2.5 million people become newly infected and 2 million
others die from AIDS. While there are several effective
drugs for treating HIV/AIDS, ongoing attempts to develop
a useful HIV-1 vaccine and a protective antiviral microbi-
cide face significant challenges and seem unlikely to be
successful in the near future [1]. In this setting, a fuller
understanding of the innate restriction mechanisms in
human cells that modulate HIV-1 replication is worth-
while.
HIV-1 infects CD4+ T-cells. The virus encodes nine genes;
three are regarded as 'structural' genes (Gag, Pol, Env),
while the other six are considered 'accessory' genes (Tat,
Rev, Nef, Vpr, Vpu, Vif). Steps in HIV-1 replication,
including the interaction of the viral envelope protein
(gp120) with the cellular CD4 receptor, reverse transcrip-
tion to generate proviral DNA, integration, RNA transcrip-
tion, viral protein synthesis, virion assembly and egress
have been reviewed elsewhere [2-5]. Here, we discuss in
brief the recent findings on apolipoprotein B mRNA-edit-
ing enzyme 3G (APOBEC3G), bone marrow stromal cell
antigen 2 (BST-2), cyclophilin A, tripartite motif protein 5
alpha (Trim5α) and cellular microRNAs (miRNAs) as
examples of host restriction factors [6-8] that target intra-
cellular HIV-1 replication.
APOBEC and Vif
APOBEC3 (A3) genes are unique to mammals and
encompass a family of cytidine deaminases that are now
believed to play an important role in the intrinsic or
innate host immune response to control retroviruses, ret-
rotransposons, hepadnaviruses, foamy viruses and, per-
haps, even some DNA viruses such as human
papillomavirus (reviewed in [6,9]). A3 genes have arisen
through gene duplication and their number varies from
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one gene in mice to seven genes in humans [10]. They
contain either one or two zinc coordinating domains. In
enzymes containing two zinc coordinating domains, gen-
erally only one (in most cases it is the C-terminal domain)
is catalytically active.
All of the A3 genes are catalytically active. However, there
is an ongoing discussion on the functional importance of
A3 catalytic activity for antiviral effects. For instance, the
inhibition of parvoviruses and retrotransposons by A3A
was found to be deaminase-independent [11-13]. Deami-
nase-independent inhibition by A3G was also reported
for other viruses such as HTLV-1 and hepatitis B virus [14-
17]. Finally, A3G and A3F were shown to inhibit HIV rep-
lication in a deaminase-independent manner (reviewed
in [6]). However, most of the data supporting deaminase-
independent mechanisms result from a transient overex-
pression of A3 proteins or are based on in vitro assays.
Indeed, there is strong evidence that HIV-1 restriction
does require A3G deaminase activity when the protein is
not transiently overexpressed [18-20]. A3G is a powerful
inhibitor of HIV-1 and several studies showed that only a
few molecules of packaged A3G are sufficient to inhibit
virus replication [20,21]. On the other hand, the inhibi-
tion of HIV-1 replication appears to require a minimum
A3G threshold level. This is suggested by the observation
that HIV-1 carrying a partially defective Vif gene was
found to replicate, albeit with delayed kinetics, in A3G
expressing CEM cells, a human cell line originally isolated
from an acute lymphoblastic leukemia [22]. Under those
conditions, viral DNA showed clear evidence of hypermu-
tation whereas viral RNA was largely unaffected, suggest-
ing a mechanism of purifying selection [22].
A3 proteins are packaged into viral particles through an
interaction with viral Gag protein and viral or cellular
RNA [23]. Vif neutralizes the antiviral activity of A3G and
A3F by inhibiting their packaging into viral particles. This
involves a proteasome mediated degradation of A3 pro-
teins as well as the degradation-independent mecha-
nism(s) [24]. Endogenous A3G appears to be much less
sensitive to degradation by Vif than transiently expressed
protein [25]. While the relative contribution of degrada-
tion-dependent or independent mechanisms is still being
debated, it is generally accepted that the inhibition of A3G
and A3F by whatever mechanism involves a direct physi-
cal interaction with Vif (Figure 1). The regions in Vif,
important for binding to A3G and A3F, appear to be over-
lapping but not identical. They map to the N-terminal
region of Vif and appear to be discontinuous [26-31].
Interestingly, the regions in A3G and A3F important for
interaction with Vif are also distinct. In A3G, residues of
126-132 in the N-terminal region were found to be suffi-
cient for Vif binding, while Vif appears to interact with a
C-terminal region of the A3F encompassing residues 283-
300 [32-34]. In fact, that A3F region is sufficient to enable
Vif binding and A3F degradation, whereas degradation of
A3G by Vif requires a region larger than that necessary for
Vif binding [32].
The structural determination of full-length A3G has so far
been unsuccessful. This is mostly due to the insolubility of
Protein interaction domains in HIV-1 Vif Figure 1
Protein interaction domains in HIV-1 Vif. The regions responsible for interaction with A3G (red) and A3F (blue) are dis-
continuous. They overlap but are not identical. The region important for interaction with the Cul5 ubiquitin ligase complex is 
marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box 
domain. The scale at the bottom indicates amino acid positions.BMC Medicine 2009, 7:48 http://www.biomedcentral.com/1741-7015/7/48
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the purified protein. Structural data are currently available
only for monomeric forms of the C-terminal catalytic
domain [35-38]. However, biochemical analyses demon-
strated that A3G forms oligomeric structures that are
mediated or stabilized by RNA [39-41]. Huthoff et al. have
identified oligomerization mutants of A3G that were
packaging incompetently and had lost their antiviral
activities [41]. Opi et al., on the other hand, identified an
oligomerization mutant that remained packaging compe-
tent and retained antiviral activity [39]. Thus, even though
A3G is likely to be recruited into viral particles as an oli-
gomer [42], A3G oligomerization does not appear to be
critical for antiviral activity, at least in transient expression
assays.
One of the intriguing properties of A3G is its ability to
assume different intracellular configurations. In activated
cells and T cell lines, A3G exists as a mixture of low molec-
ular mass (LMM) and high molecular mass (HMM) com-
plexes, and it has been proposed that only the LMM form
of A3G has antiviral activity [43]. A3G exerts its antiviral
effect during the early phase of virus replication. In order
to do so, the protein has to be packaged into virions from
the virus-producing cell. A3G expressed in target cells does
not generally inhibit virus replication. A notable excep-
tion is resting CD4+ T cells. In these cells A3G exists pre-
dominantly in the LMM configuration and was shown to
impose a potent post-entry restriction on HIV infection
[43]. This view was recently challenged by Kamata et al.
who could not confirm the involvement of A3G in the
post-entry restriction of HIV-1 [44]. Thus, the relative con-
tribution of A3G to the resistance of quiescent T cells to
HIV infection remains to be resolved.
Vpu and BST-2
It is generally accepted that Vpu regulates the detachment
of otherwise complete and infectious virions from the cell
surface [45,46]. Interestingly, the ability to enhance virus
release is not unique to Vpu. In fact, some HIV-2 isolates
have been known to encode a Vpu-like activity in their
Env glycoproteins [47-50]. Intriguingly, a similar Vpu-like
activity has now also been shown for the Nef protein of
several simian immunodeficiency viruses, including SIV-
mac and SIVagm [51,52].
Vpu-dependent virus release is host cell-dependent [53].
Indeed, several other host factors have been identified
whose overexpression was associated with reduced virus
release. These include the Vpu binding protein UBP [54],
TASK-1, a human potassium channel protein, [55] and
the recently identified host factors BST-2 (also referred to
as tetherin, CD317, or HM1.24 [56,57]) and CAML (cal-
cium modulating cyclophilin ligand) [58]. Among those,
BST-2 is of particular interest since its cell type-specific
expression most closely matches that of Vpu-dependent
cell types. Silencing the BST-2 expression in HeLa cells by
siRNA or shRNA (short hairpin ribonucleic acid) rendered
virus release from these cells Vpu-independent [56,57].
A functional Vpu-BST-2 interaction was first reported in a
quantitative membrane proteomics study where Vpu
expressed from an adenovirus vector was found to reduce
cellular expression of BST-2 in HeLa cells [59]. Intrigu-
ingly, BST-2 expression is cell type dependent and is
induced by interferon treatment [56,57,60,61] which is
consistent with the previous observation that cell lines
that did not normally require Vpu for efficient virus
release became Vpu-dependent upon being treated with
interferon [60].
How does BST-2 inhibit virus release? BST-2 is a 30-36
kDa type II transmembrane glycoprotein [62]. The protein
has both an N-terminal transmembrane domain and a C-
terminal glycosyl-phosphatidylinositol (GPI) anchor [63]
(Figure 2). This has led to a model, in which BST-2, by
means of its N-terminal transmembrane domain and its
C-terminal GPI anchor, tethers otherwise fully detached
virions to the producer cell [56]. Such a model is consist-
ent with the observation that Vpu-defective particles can
be released by protease treatment [46] or by physical force
[45]. Particles released by the latter method were found to
be fully infectious [45]. The tethering model is elegant and
simple but it still awaits formal experimental validation.
Interaction of BST-2 with HIV-1 proteins Figure 2
Interaction of BST-2 with HIV-1 proteins. Vpu inter-
acts with BST-2 through its transmembrane domain. Interac-
tion of BST-2 with Nef involves the cytoplasmic domain. The 
interaction of HIV-2 Env with BST-2 has not been mapped, 
but may involve the ectodomain. Proposed interaction points 
are indicated by red zig-zag lines. Myr: Nef myristoylationl; 
gpi: glycosyl-phosphatidylinositol anchor.BMC Medicine 2009, 7:48 http://www.biomedcentral.com/1741-7015/7/48
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Somewhat unexpectedly, Vpu-deficient virions that were
separated from the cell surface by physical force did not
contain detectable amounts of BST-2 [61] even though the
electron micrograph data imply that BST-2 not only teth-
ers particles to the virus producing cell but crosslinks viri-
ons among each other [45,56].
How does Vpu counteract the BST-2 imposed restriction
of virus release? Recent data suggest that the BST-2 trans-
membrane (TM) domain is critical for interference by Vpu
[64-66] consistent with the previous observation of the
importance of the Vpu TM domain for the regulation of
virus release [67-69]. This suggests a direct physical inter-
action of Vpu and BST-2. Indeed, Vpu was found to inter-
act with BST-2 in HeLa cells [70]. It is unclear how Vpu
inhibits BST-2. One simple way of interference would be
to down regulate the protein from the cell surface. Indeed,
several studies have noted that Vpu can down regulate
BST-2 [57,61,71] although Vpu does not seem to increase
the rate of BST-2 endocytosis [72]. This suggests that Vpu
may affect the resupply or the surface delivery of BST-2, a
function that could be exerted from an intracellular loca-
tion such as the trans-Golgi compartment [70,73]. Inter-
estingly, Vpu was found to reduce total cellular levels of
endogenous as well as exogenously expressed BST-2
[59,61]. How this is accomplished is not yet completely
clear. However, it has been suggested that antagonism of
BST-2 by Vpu involves proteasomal degradation by Vpu
[74,75]. It was also reported to encompass a β-TrCP (beta
transducing repeat containing protein)-dependent endo-
lysosomal pathway [70,72]. The involvement of β-TrCP in
the virus release activity of Vpu necessitates the conserva-
tion of Vpu's TrCP binding motif. However, mutation of
this motif was previously found to only partially affect the
virus release activity of Vpu [57,76,77] and in more recent
studies the mutation of the TrCP-binding site in Vpu
(Vpu26) did not affect replication kinetics in a variety of
cell types, including the peripheral blood mononuclear
cells [61]. Expression of the TrCP binding-deficient Vpu26
had no effect on BST-2 stability. To the contrary, it
appeared to stabilize or even increase the BST-2 surface
expression [61]. Thus, more work needs to be done to sort
out which of the effects of Vpu on BST-2 (surface expres-
sion, degradation or intracellular sequestration) are criti-
cal for enabling enhanced virus release.
The effects of BST-2 are not restricted to lentiviruses. They
have also been shown to affect Ebola virus release [78,79].
Furthermore, the inhibition of HIV-1 virus release is not
limited to human BST-2 but is also observed in mouse, rat
and monkey BST-2 [65,74]. However, only the human
BST-2 is sensitive to Vpu. Finally, the ability of HIV-2 Env
and SIV (simian immunodeficiency virus) Nef to antago-
nize BST-2 appears to involve cell surface down modula-
tion of BST-2. However, unlike Vpu, neither Nef nor HIV-
2 seems to affect the stability of BST-2 [51,70]. Although
Vpu, targets the BST-2 TM domain, Nef targets the cyto-
plasmic domain (Figure 2) [51,52]. The site(s) in BST-2
critical for its sensitivity to HIV-2 Env have not yet been
mapped. Recently, however, it was noted that the Vpu-like
activity of HIV-2 Env was regulated by a single amino acid
difference in the ectodomain of its TM subunit [80]. It
will, therefore, be interesting to see if HIV-2 Env targets
the BST-2 ectodomain.
A final point concerns the question of whether or not BST-
2 deserves the label of restriction factor. It is true that BST-
2 potently inhibits the release of viral particles and that
there does seem to be a selective pressure to maintain Vpu
expression, at least in the SHIV (simian-human immuno-
deficiency virus) model [81]. However, Vpu is not abso-
lutely essential for viral replication and there are primary
HIV-1 isolates that lack a functional Vpu gene due to the
mutation of the initiation codon [82]. The inhibition of
Vpu will reduce virus release but that does not prevent
viral spread. Instead, virus replication will simply shift
from a cell-free mode to a cell-to-cell mode. This finding
likely explains why Vpu-deficient viruses replicate in tis-
sue culture with the same kinetics as wild type virus
[45,83-85]. Thus, BST-2 is a restriction factor in the sense
that it limits the release of viral particles from infected
cells. However, it may not be a restriction factor in the
sense that it blocks the spread of virus in an infected indi-
vidual.
Cyclophilin
In the early 1990s cyclophilin A (Cypa) was reported to be
a cellular factor that binds HIV-1 capsid protein (CA), but
not the CA of other lentiviruses such as SIVmac239 [86-
88]. Recently, it was shown that it also interacts with the
CA of some HIV-2 isolates, with SIVagmtan and with FIV
(feline immunodeficiency virus) [89-91]. Cypa is a small
globular protein that binds to proline-containing peptides
via its hydrophobic pocket and is believed to have subtle,
but global, effects on protein folding within cells. Among
the specific cellular functions of Cypa, it regulates the
nuclear export of Zpr1 (zinc finger protein 1) in yeast [92]
and the kinase activity of Itch (inducible T-cell kinase) in
CD4+ T cells [93]. As a complex with the immunosup-
pressive drug cyclosporine, it is a potent inhibitor of the
CA-dependent phosphatase calcineurin in T cells [94].
Interaction with HIV-1 CA does, indeed, involve a critical
proline residue [95] and binding of CypA catalyzes a con-
formational change in CA [96].
CypA acts within the target cell soon after HIV-1 infection
[95,97,98], in some cases to promote infection and in
others to inhibit infection [97,99,100]. Sometimes the
effect is at the level of reverse transcription [95]. At other
times the effect of CypA is evident later, perhaps at theBMC Medicine 2009, 7:48 http://www.biomedcentral.com/1741-7015/7/48
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level of nuclear entry [100,101]. It is generally thought
that CA indirectly regulates reverse transcription via its
effects on an ill-defined process called uncoating (Figure
3). However, CA remains associated with nascent viral
cDNA, may dock to the nuclear pore and does seem to be
a critical determinant in HIV-1's ability to cross the
nuclear pore or even to integrate into host chromosomal
DNA [100,102-104]. The simplest explanation for the
diverse effects of CypA is that it regulates CA interaction
with host factors, either uncoating factors, nuclear pore
components or restriction factors that act in a similar fash-
ion to TRIM5 [105-107] (Figure 3).
As discussed below, characterization of the varied effects
of CypA steered investigators to the discovery of TRIM5 as
an innate, species-specific anti-HIV-1 factor in the cells of
non-human primates [106,107]. In the future, the provi-
ral and antiviral effects of CypA in different human cell
types may guide the discovery of similar factors acting in
human cells [107-110]. A more detailed structural analy-
sis of the HIV-1 CA lattice [111] may reveal how CypA
alters the CA conformation and, thus, the accessibility of
antiviral factors such as TRIM5. A modest inhibition of
viral load by cyclophilin A-binding drugs (non-immuno-
suppressive analogues of cyclosporine) was seen in some
individuals with HIV-1 infection [112], leaving open the
possibility that such drugs might play a role in the clinic
in the future.
TRIM5
Cells from South American owl monkeys potently inhibit
HIV-1 transduction [113]. This HIV-1 restriction activity
was examined in great detail because of its apparent
dependence upon CypA [105-107]. These studies led to
the cloning of an essential factor, the TRIM5-CypA fusion
gene [106]. A similar anti-HIV-1 restriction activity in rhe-
sus macaque cells was shown to be due to TRIM5alpha
[114]. TRIM5alpha orthologues with anti-retroviral activ-
ity have been observed in most primate species, as well as
in cows [115,116] and rabbits [117]. The gene is deleted
in dogs and truncated in cats [118]. Rodents have multi-
ple copies of the gene, though antiviral activity has not
been demonstrated [119]. The owl monkey gene was cre-
ated by retrotransposition of a CypA cDNA into the
TRIM5 locus [106,120,121]. Amazingly, a TRIM5-CypA
fusion allele was created by an independent retrotranspo-
sition event in Asian macaques [122-125].
TRIM5 is one of the more than 70 tripartite motif genes in
the human genome. Tripartite refers to proteins bearing a
RING finger, a B-box and a coiled-coil domain. The two
latter domains promote TRIM5 multimerization and are
almost always required for anti-HIV-1 restriction activity
[126,127]. The TRIM5 RING finger has E3 ubiquitin ligase
activity in vitro and in vivo [128-130] and, while not strictly
required for restriction activity, it clearly plays an impor-
tant role in TRIM5-mediated restriction. This apparent
paradox has been explained by the finding that TRIM5
blocks HIV-1 infection at more than one step, reverse tran-
scription and nuclear import [101,131,132].
The CypA domain in the TRIM5-CypA fusions is clearly a
CA-binding determinant [106,120]. A single amino acid
The effect of host cell cyclophilin A on HIV-1 transduction Figure 3
The effect of host cell cyclophilin A on HIV-1 trans-
duction. Host cell cyclophilin A (shown in green) binds to 
the HIV-1 CA and regulates CA-recognition by host cell 
restriction factors. In some cases, cyclophilin A promotes 
HIV-1 CA recognition by these factors (for example, by rhe-
sus macaque TRIM5alpha). In other cases, human cells for 
example, cyclophilin A seems to prevent recognition by these 
factors. The effect of cyclophilin A is, therefore, determined 
by the effect of the restriction factor, which may act at the 
time of reverse transcription, nuclear import, or integration.BMC Medicine 2009, 7:48 http://www.biomedcentral.com/1741-7015/7/48
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change in the CypA domain distinguishes the owl mon-
key and macaque proteins which alters retroviral restric-
tion specificity [122]. It has been much harder to
demonstrate CA-binding activity for the PRY-SPRY
domain (a domain present in the Dictystelium discoi-
deum dual-specificity kinase and the PYRIN protein gene
family) of the TRIM5alpha isoform [133-135], apparently
because its interaction is much weaker than that of the
CypA-CA [127]. It is allele specific differences in the PRY-
SPRY domain that determine the differences in retroviral
restriction specificity for different TRIM5alpha ortho-
logues [136-139].
The most important question that remains unanswered
about TRIM5 is how it restricts retroviral infection. Is it
simply that a multimer of TRIM5 binds to incoming vir-
ion cores and prematurely uncoats them? Or is the mech-
anism more complicated, requiring accessory factors (see
Figure 4) [107-109,140]? What, if any, is the role of ubiq-
uitin in the restriction mechanism? What is the three-
The effect of TRIM5 on retroviral transduction Figure 4
The effect of TRIM5 on retroviral transduction. In the absence of a restrictive TRIM5α orthologue (No TRIM5), the ret-
roviral genomic RNA is reverse transcribed, translocated to the nucleus and integrated. In the presence of a restrictive allele of 
TRIM5, retroviral infection is blocked at the level of reverse transcription and, probably, also at the level of nuclear import. 
According to some investigators, TRIM5 binding to the incoming virion capsid is sufficient to disrupt infection (sufficiency 
model). According to other investigators, the antiviral effects of TRIM5 require as yet to be identified, cellular cofactors (cofac-
tor model).BMC Medicine 2009, 7:48 http://www.biomedcentral.com/1741-7015/7/48
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dimensional structure of TRIM5 and how does it recog-
nize the virion core? TRIM5 forms cytoplasmic bodies but
the significance of these remains unclear, especially since
the endogenous protein has not been visualized.
Non-coding microRNAs and RNA-silencing
Although restriction factors have traditionally been
thought of as proteins, recent findings suggest similar
roles played by non-coding RNAs. This concept seems to
make sense because, while less than 2% of the human
genome encode for proteins, >70% of human DNA are
transcribed into non-coding RNAs (ncRNAs) [141].
NcRNAs come in several forms including siRNA, miRNA,
and piRNA with each being regulated differently [142-
147]. Amongst these RNAs, the best studied is perhaps the
~21-23 nucleotide long microRNA (miRNA). The biogen-
esis of miRNAs has been reviewed in detail elsewhere
[146] and currently more than 800 discrete members are
listed in the human miRNAs database (see http://micro
rna.sanger.ac.uk).
For RNA interference (RNAi) activity, miRNAs assemble
into RNA-induced silencing complexes (RISC) which con-
tain an Argonaute protein with additional RNA-binding
co-factors such as TRBP (TAR RNA-binding protein) [148-
150]. An active miRNA-RISC silences a target mRNA via
limited, and sometimes imperfect, base-pairing between
the 5'-positioned 2-8 nucleotides of the miRNA (the 'seed'
region) [151] and the mRNA. Currently, it is held that a
miRNA primarily targets the 3' untranslated region (UTR)
of a mRNA. However, coding sequences and the 5' UTR of
mRNAs can serve also as miRNA-substrates [152-154].
Indeed, a single miRNA through 'imperfect' (wobbled)
base-pairing with mRNA-targets could potentially recog-
nize and regulate the expression of up to one hundred dif-
ferent mRNAs [155].
miRNA-restriction of HIV-1
MiRNAs are used by plants and lower eukaryotic cells to
restrict infecting viruses [156]. In higher eukaryotes, the
same functional complement of miRNA components and
RNA-silencing machinery are conserved. However, it has
been debated whether mammals might have extinguished
this ncRNA-based antiviral strategy [157-160]. To date,
experimental findings, as outlined below, support the
idea that mammals continue to employ ncRNAs to
'silence' viruses. First, short interfering RNAs (siRNAs)
[161], piwi-interacting RNAs [142,162] and Dicer-proc-
essed miRNAs [163] have been shown to suppress mam-
malian endogenous retroviruses in somatic, germ and
mouse embryonic stem (ES) cells. Secondly, bioinformat-
ics analyses have extended this notion of antiviral defense
to a plethora of human miRNAs that can target many
types of viruses [164,165]. Specifically, miRNA-regulation
of HIV-1 infection has been experimentally verified and
independently reported by four groups of investigators
[166-169]. Thirdly, recent results show that human cells
can process HIV-1 RNAs into small ncRNAs that could
potentially interdigitate into the cellular RNAi pathways
[170]. Collectively, these discrete findings converge to
suggest that RNAi-restriction pathways in human T-lym-
phocytes and macrophages are operative for HIV-1 repli-
cation (Figure 5).
Suppression of RNAi enhances HIV-1 replication
Whether or not RNAi is a physiological mechanism for
modulating viral replication can be addressed by asking
what happens to an HIV-1 infection when the infected
cells are attenuated for their RNAi activity. The RNAi path-
way has been deliberately disabled in human cells by the
knock down of either the Dicer protein [171] or the RISC
components [172] and such suppressions have enhanced
HIV-1 replication in cells. Separately, when heterologous
RNA-silencing suppressors (RSS), such as the Vaccinia
virus E3L protein, influenza A virus NS1 protein, Ebola
virus VP35 protein [173] or NS3 protein of Rice Hoja
Blanca virus [174], were over expressed in human cells
(Table 1) HIV-1 replication in RSS-expressing cells was
also considerably enhanced over that of control cells. The
most simple interpretation of these results is that the RSS
proteins encoded by the viruses repressed a physiologi-
Schematic representations of roles played by small non-cod- ing RNAs in HIV-1 replication Figure 5
Schematic representations of roles played by small 
non-coding RNAs in HIV-1 replication. Integrated HIV-
1 provirus is transcribed into viral RNA which can be tar-
geted by cellular miRNAs. HIV-1 transcripts can also be 
processed into small ncRNAs that could function in cellular 
RNAi pathway(s). The viral trans-activation responsive TAR 
RNA has been reported to be processed into a viral miRNA 
which could act to modulate the expression of cellular 
mRNAs.BMC Medicine 2009, 7:48 http://www.biomedcentral.com/1741-7015/7/48
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cally restrictive cellular RNAi on HIV-1 and that the neu-
tralization of this RNAi directly increased viral replication.
The generality of RNAi as a mammalian antiviral mecha-
nism is illustrated by the finding that many viruses encode
RSS proteins (Table 1) and that, when cellular RNAi is
suppressed, the replication of vesicular stomatitis virus
(VSV) [175] and influenza A virus [176] is also enhanced.
Collectively, the extant observations are consistent with a
conserved mammalian ncRNA/Dicer-RISC/RNAi innate
restriction pathway(s) that guards human cells against
endogenous and exogenous viruses.
At what point of an infection might HIV-1 encounter cel-
lular RNAi-restriction? Berkhout et al. reported that the
infecting HIV-1 genome is initially sheathed [177] to repel
RNAi surveillance. However, at a later stage the RNAi
machinery can access and process HIV-1 RNA, as evi-
denced by the cellular production of virus-encoded TAR
(trans-activation responsive RNA) miRNAs [178-180]
(Figure 5). Nevertheless, despite the RNAi activity of the
cell, in most settings, HIV-1 continues to replicate. This
replication is partly explained by the action of the virus-
encoded arginine-rich RNA-binding protein, Tat, which
acts in an RNA-binding dependant manner [181] as an
RNAi-suppressor [182] and by the viral TAR RNA which
acts as an RNAi-decoy [183]. The function of HIV-1 Tat as
an RNAi-suppressor has been characterized by several
investigators and appears to be widely conserved in
diverse experimental settings [182,184-186]. Finally, as
already noted, RNAi-suppressors appear to be commonly
conserved in many mammalian viruses (Table 1). Indeed,
viruses such as herpes simplex do employ RNAi-suppres-
sion for their replication in human cells [187].
Cellular RNAi virus interaction has been speculated to
reshape viral genome sequences overtime [157,188].
Accordingly, it serves viruses, such as HIV-1, well to evolve
functions that can alter the miRNA expression profile of
the cell to repress virus-noxious miRNAs and to enhance
virus-propitious miRNAs. Evidence that such changes
occur during viral infection has been reported
[171,189,190], suggesting a dynamic strike-counterstrike
interplay between the virus and the host [191,192]. Future
investigations are needed in order to better understand
how RNA-based antiviral restriction complements pro-
tein-based restriction.
Concluding remarks
We have raised several examples of host cell factors that
can act to impede HIV-1 replication. The emerging sce-
nario suggests that a number of different steps in HIV-1
replication (for example, uncoating, reverse transcription,
transcription and virus release) can be targeted by
APOBEC3G, cyclophilin, TRIM5α, BST-2 and RNAi.
Remarkably, the cellular stratagems against the virus are
apparently moderated by HIV-1 encoded countermeas-
ures (for example, Vif, Vpu and Tat). Hence, intricate
strike-counterstrike interactions apparently govern the
ultimate outcome of HIV-1/cell infection. The overall pic-
ture is likely to be even more complex. Recent genome-
wide screenings have revealed many hundreds of host cell
proteins that appear to be needed in order to activate HIV-
1 replication in human cells [193-196]. Additional
genome-wide screens will undoubtedly uncover an
equally numerous number of host cell factors that restrict
HIV-1 replication. The limited examples of HIV-1 restric-
tion factors presented here represent a prelude to the
many more restriction entities that still await identifica-
Table 1: Examples of RNA silencing suppressors encoded by several viruses.
Virus Viral Suppressors References
Adenovirus VA RNA Lu 2004 [199]; Andersson 2005 [200]; Xu 2007 [201]
HCV Core protein Chen 2008 [202]; Wang 2006 [203]
Ebola VP35 protein Haasnoot 2007 [184]
Influenza A virus NS1 protein Li 2004 [204]; Delgadillo 2004 [205]; Bucher 2004 [206]; Haasnoot 2007 [184]; de Vries 
2009 [186]
Nodamura Virus NoV B2 protein Sullivan 2005 [207]
Primate Foamy Virus Tas protein Lecellier 2005 [208]
HIV Tat protein, TAR RNA Bennasser 2005 [182]; Haasnoot 2007 [184]; Bennasser 2006 [183]; Qian 2009 [185]
Rice Hoja Blanca Virus NS3 Schnettler 2009 [174]
[This table is modified after Grassmann and Jeang, Ref. [159]].BMC Medicine 2009, 7:48 http://www.biomedcentral.com/1741-7015/7/48
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tion. The next challenge is to elucidate these entities and
then apply them to the development of additionally use-
ful interventions against HIV-1/AIDS. For example, the
further discovery of cellular factors which obstruct HIV-1
integration [197] could serve to aid the development of
novel adjunct therapies that synergize with extant inte-
grase inhibitors [198]. Exciting progress in antivirals lies
ahead.
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